| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | STF-62247 | GDSC1000 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | -0.0028 | 0.9 |